PlainRecalls
FDA Drug Critical Class I Terminated

Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047

Reported: March 30, 2022 Initiated: March 4, 2022 #D-0750-2022

Product Description

Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047

Reason for Recall

Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.

Details

Recalling Firm
Fresenius Kabi USA, LLC
Units Affected
118,040 vials
Distribution
Nationwide USA
Location
Lake Zurich, IL

Frequently Asked Questions

What product was recalled?
Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047. Recalled by Fresenius Kabi USA, LLC. Units affected: 118,040 vials.
Why was this product recalled?
Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 30, 2022. Severity: Critical. Recall number: D-0750-2022.